SCHEMBL5136568

SCHEMBL5136568

CCCCN(Cc1ccc(OC(F)F)cc1)Cc1c(-c2ccccc2OC)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 3/20 0.38
C5AR1 P21730 1/20 0.36
CASR P41180 1/20 0.36
BCL2L2 Q92843 1/20 0.35
HTR1A P08908 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
PDE2A O00408 1/20 0.34
ATP4A P20648 2/20 0.34
ATP4B P51164 2/20 0.34
DRD2 P14416 2/20 0.34
DRD3 P35462 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
PPARG P37231 2/20 0.33
PPARA Q07869 2/20 0.33
TSHR P16473 1/20 0.33
PAX8 Q06710 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136254 0.92 C5AR1 (0.39) C5AR1CASRBCL2L2HTR1AHTR2C
SCHEMBL650283 0.90 C5AR1 (0.42) CRHR1C5AR1ATP4AATP4BDRD2
SCHEMBL5137495 0.89 ATP4A (0.39) CRHR1C5AR1PDE2AATP4AATP4B
SCHEMBL5136974 0.88 ATP4A (0.39) CRHR1C5AR1ATP4AATP4BDRD2
SCHEMBL5138077 0.88 C5AR1 (0.39) CRHR1C5AR1CASRBCL2L2HTR1A
SCHEMBL650201 0.87 C5AR1 (0.41) CRHR1C5AR1ATP4AATP4BDRD2
SCHEMBL648163 0.87 C5AR1 (0.41) CRHR1C5AR1ATP4AATP4BDRD2
SCHEMBL652364 0.87 C5AR1 (0.41) CRHR1C5AR1ATP4AATP4BDRD2
SCHEMBL649935 0.87 C5AR1 (0.41) CRHR1C5AR1ATP4AATP4BDRD2
SCHEMBL652236 0.86 C5AR1 (0.42) CRHR1C5AR1ATP4AATP4BDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed